Overview
- Lilly’s Q4 revenue rose 43% to $19.29 billion and adjusted EPS reached $7.54, beating LSEG consensus.
- The company guided 2026 revenue to $80–$83 billion and EPS to $33.50–$35, implying roughly 25% growth with consensus still modeling 21%+ revenue and 40%+ adjusted‑earnings gains.
- Mounjaro sales climbed 110% to $7.4 billion and Zepbound rose 123% to $4.3 billion in Q4, highlighting GLP‑1 strength.
- Goldman Sachs raised its price target to $1,260 and JPMorgan to $1,300, maintaining Buy/Overweight ratings after the update.
- Lilly says it expects a U.S. launch of oral GLP‑1 orforglipron in Q2 2026, as independent forecasts trim long‑term obesity‑drug market sizes due to pricing pressure and new competition.